A drug development and discovery company focused on autoimmune and cancers indications.

4SC to present development of resminostat and preclinical drug candidates at EORTC-NCI-AACR symposium 4SC , a drug development and discovery company focused on autoimmune and cancers indications, today announced that it’ll present 4 posters and respective abstracts that highlight the advancement of its lead oncology compound resminostat and many preclinical drug applicants at the 22nd EORTC-NCI-AACR symposium from 16 – 19 November, 2010 in Berlin, Germany. A synopsis is roofed by These data on the clinical development activities of the pan-HDAC inhibitor resminostat, currently in Phase II trials in hepatocellular tumor and Hodgkin’s lymphoma, a profile of its second, selective-HDAC inhibitor 4SC-202 and an introduction to 4SC-207, an anti-mitotic cell routine blocker. ‘Our presence at EORTC underlines our commitment to developing oncology candidates that will offer an improved and targeted standard of look after cancer patients,’ said Bernd Hentsch, Chief Advancement Officer, 4SC Click here .